ClinicalTrials.gg
CompletedNCT07600944Updated Aug 14, 2026

Comparison of the Pharmacokinetics (PK)and Pharmacodynamics (PD)Biosimilarity of Insulin Aspart Injections After Single-Dose Subcutaneous Administration to Healthy Volunteers

An interventional study of Insulin Aspart Injection(UBLIN®) and Insulin Aspart Injection(NovoRapid®) in Pharmacokinetics and Pharmacodynamics, sponsored by Zhuhai United Laboratories Co., Ltd.. Completed at 1 site in China. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-14.

Sponsored by Zhuhai United Laboratories Co., Ltd. (part of The United Laboratories International Holdings Limited) · Not applicable, Interventional, and Health services research

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The present study is designed to compare the pharmacokinetic, pharmacodynamic and safety characteristics of UBLIN® (test product) and NovoRapid® (reference product) in healthy male participants. The treatment consists of one single dose of the test or reference product, administered during each of the two study periods, separated by 7 days between dosing. A total of 44 participants will be enrolled in this trial and randomized in a 1:1 ratio into two groups (A/B), stratified by race (Asian, non-Asian).

02

Conditions studied

  • Pharmacokinetics and Pharmacodynamics
03

In context

Lead sponsor

Zhuhai United Laboratories Co., Ltd. is the lead sponsor of 5 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male participants aged 18 to 55 years (inclusive).
  2. Body weight: Male ≥ 50.0 kg, [BMI = weight (kg)/height2 (m2)] between 19.0 and 28.0 kg/m2 (inclusive).
  3. Individuals with normal vital signs or abnormalities without clinical significance (normal reference range: 90 mmHg ≤ systolic blood pressure (supine) \< 140 mmHg, 60 mmHg ≤ diastolic blood pressure (supine) \< 90 mmHg, 60 beats/min ≤ pulse \< 100 beats/min, 36.0°C ≤ body temperature ≤ 37.0°C).
  4. Normal glucose tolerance (3.90 mmol/L \< fasting plasma glucose (FPG) \< 6.10 mmol/L, and 2-hour postprandial blood glucose after oral glucose tolerance test (OGTT) \< 7.80 mmol/L), glycosylated value between 4.0% and 6.0% (inclusive), and normal insulin secretion function (as determined by the investigator based on insulin release test results).
  5. Has fully understood the nature, significance, potential benefits, possible inconveniences, and potential risks of the trial before participation, voluntarily participates in this clinical trial, being able to communicate well with the investigator, complying with all study requirements, and has signed the written form.

Exclusion criteria

Exclusion Criteria:

  1. History of specific allergies (e.g., asthma, urticaria, eczema), or those allergic to any drug, food, or pollen, or known to be allergic to insulin;
  2. History of hereditary galactose intolerance, lactase deficiency, or glucose-galactose malabsorption;
  3. Has abnormal conditions requiring exclusion, including but not limited to system disorders of the nervous, cardiovascular, hematological and lymphatic, immune, renal, hepatic, gastrointestinal, respiratory, metabolic, and skeletal systems, especially a history of hypoglycemia, hypokalemia, orthostatic hypotension, syncope or blackout, diabetes mellitus, or a family history of diabetes mellitus (first-degree relatives);
  4. Has a history of severe vomiting, diarrhoea within 7 days prior to the trial, or has any other disease or physiological condition that may interfere with the trial results;
  5. Has undergone surgery within 3 months prior to the study, or plans to undergo surgery during the study period; or has undergone any surgery that may affect drug absorption, distribution, metabolism, or excretion;
  6. Has a history of asthma or epilepsy;
  7. Has participated in any other product or device clinical trial and received investigational product within 6 months prior to the study;
  8. Has taken any medications that alter liver enzyme activity within 28 days prior to the trial (common liver enzyme inducers: barbiturates (phenobarbital is the most common), carbamazepine, aminoglutethimide, griseofulvin, meprobamate, phenytoin, glutethimide, rifampicin, dexamethasone; common liver enzyme inhibitors: chlorpromazine, cimetidine, ciprofloxacin, metronidazole, chloramphenicol, sulfonamides);
  9. Has taken any medications that affect the hypoglycemic effect of insulin within 28 days prior to the trial (e.g., , danazol, diazoxide, diuretics, epinephrine, albuterol, terbutaline, glucagon, growth hormone, thyroid hormones, beta-blockers, etc.);
  10. Has used any prescription drugs, over-the-counter drugs, health products, traditional Chinese medicines, or received vaccinations within 14 days prior to the trial;
  11. Has any clinically significant abnormality identified by the investigator in general physical examination, laboratory tests (including hematology, blood biochemistry, coagulation, urinalysis, etc.), or 12-lead within 14 days prior to the study;
  12. Has clinically significant abnormalities in glutamic acid decarboxylase autoantibodies (GAD), islet cell cytoplasmic autoantibodies (ICA), or insulin autoantibodies (IAA) results as judged by the investigator;
  13. Has clinically significant abnormalities in surface antigen, antibody, (HIV) antibody, or syphilis-specific antibody tests;
  14. Has a breath alcohol test result > 0.0 mg/100 mL or a positive drug abuse screening;
  15. Has used any illicit drugs within one year prior to the trial;
  16. Has consumed more than 14 units of alcohol per week within 3 months prior to the trial (1 unit = 17.7 mL of ethanol, i.e., 1 unit = 354 mL of beer with 5% alcohol, or 44 mL of liquor with 40% alcohol, or 147 mL of wine with 12% alcohol), or is unable to abstain from alcohol during the trial;
  17. Has smoked more than 5 cigarettes per day on average within 3 months prior to the trial, or is unable to stop using any tobacco products or nicotine-containing products (e.g., nicotine patches, chewing gum, etc.) during the trial;
  18. Has excessively consumed tea, coffee, and/or caffeine-rich beverages (more than 8 cups per day, 1 cup = 250 mL) within 3 months prior to the trial;
  19. Has consumed any food or beverages rich in caffeine/xanthine or other special ingredients (such as strong tea, coffee, chocolate, cola, animal offal, grapefruit, grapefruit juice, pitaya, mango, etc.) from screening to 3 days prior to dosing and the diet is judged by the investigator to potentially affect the absorption, distribution, metabolism, and excretion of the drug, or is unable to abstain from such foods or beverages during the trial;
  20. Has had blood loss or donated more than 200 mL of blood, received a blood transfusion, or used blood products within 3 months prior to the trial, or plans to donate blood during the trial or within 6 months after the last dose;
  21. Has a pregnancy or sperm donation plan from 2 weeks prior to study start until 6 months after the last dose of study drug, and is unwilling or fails to take effective ;
  22. Is unable to eat normally or has swallowing difficulties, has special dietary requirements, or is unable to comply with the standardized dietary protocol for the trial;
  23. Is engaged in high-altitude work, motor vehicle driving, or other mechanical operations with potential safety hazards;
  24. Has poor tolerance to venipuncture, or a history of syncope induced by blood or needle exposure;
  25. Has been deemed by the investigator to have poor compliance or has any other factors unsuitable for participation in this trial.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    UBLIN®

    Single subcutaneous administration of UBLIN® in dose 0.2 U/kg

    Drug: Insulin Aspart Injection(UBLIN®)

  • Active comparator
    NovoRapid®

    Single subcutaneous administration of NovoRapid® in dose 0.2 U/kg

    Drug: Insulin Aspart Injection(NovoRapid®)

Interventions

  • DrugInsulin Aspart Injection(UBLIN®)

    The dosage per cycle is 0.2 U/kg

  • DrugInsulin Aspart Injection(NovoRapid®)

    The dosage per cycle is 0.2 U/kg

06

What researchers measure

Primary outcomes

  1. Area Under the Curve (AUC) of Insulin Aspart Plasma Concentration From Time 0 to the Time of Last Measurable Concentration, AUC0-t

    Time frame: 0 to 10 hours

  2. Peak Plasma Concentration of Insulin Aspart, Cmax

    Time frame: 0 to 10 hours

  3. Area Under The Curve (AUC) of Glucose Infusion Rate(GIR) From Time 0 To End Of Clamp At Time T, AUCGIR0-t

    Time frame: 0 to 10 hours

  4. Maximum Glucose Infusion Rate, GIRmax

    Time frame: 0 to 10 hours

Secondary outcomes

  1. Area Under the Curve (AUC) of Insulin Aspart Plasma Concentration From Time 0 to 2 Hours Post-Dose, AUC0-2h

    Time frame: 0 to 2 hours

  2. Area Under the Curve (AUC) of Insulin Aspart Plasma Concentration From 2 Hours Post-dose to the Time of Last Measurable Concentration, AUC2-t

    Time frame: 2 to 10 hours

  3. Time to Reach Peak Plasma Concentration of Insulin Aspart, Tmax

    Time frame: 0 to 10 hours

  4. Elimination Rate Constant, λz

    Time frame: 0 to 10 hours

  5. Half-Life of Insulin Aspart, t1/2

    Time frame: 0 to 10 hours

  6. Area Under The Curve (AUC) of Glucose Infusion Rate(GIR) From Time 0 to 2 Hours Post-Dose , AUCGIR0-2h

    Time frame: 0 to 2 hours

  7. Area Under The Curve (AUC) of Glucose Infusion Rate(GIR) From 2 Hours Post-dose To End Of Clamp At Time T, AUCGIR2-t

    Time frame: 2 to 10 hours

  8. Time Until Maximum Glucose Infusion Rate Is Reached, TGIRmax

    Time frame: 0 to 10 hours

  9. Time To Onset Of Action, Tonset

    Time frame: 0 to 10 hours

07

Study locations

1 site
  • The Second Affiliated Hospital of Xingtai Medical College (Xingtai Cancer Hospital)
    Xingtai, Hebei 054000, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2026 to primary completion in Jun 2026, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2026
First posted
May 22, 2026
StartActual
May 6, 2026
Primary completionActual
Jun 13, 2026
CompletionActual
Jul 3, 2026
Last update
Aug 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07600944
Responsible party
Sponsor
First posted
May 22, 2026
Start date
May 6, 2026
Primary completion
Jun 13, 2026
Completion
Jul 3, 2026
Last update
Aug 14, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion